Viral Genetics Inc. (VRAL) and Scott & White Have Agreed to Develop Clinical Trials Focused on Metabolic Disruption in Cancer Patients
10/14/2010 9:32:52 AM
SAN MARINO, Calif.--(BUSINESS WIRE)--Trials are being organized for a new therapeutic approach to treating cancer, under exclusive license by Viral Genetics, Inc., (Pinksheets: VRAL). According to Scott & White Healthcare Senior Vice President for Research Richard E. Beswick, M.D., who is also assistant dean of research at the Texas A&M Health Science Center College of Medicine, the trials will be conducted at the Glenda Tanner Vasicek Cancer Treatment Center, located at Scott & White in Temple, Texas.
comments powered by